Single-dose fosfomycin 3 g,
does it really help with Clinical cure of acute uncomplicated cystitis in nonpregnant women with a single 3-g dose?
research showsSingle-dose fosfomycin clinically cures many cases of acute uncomplicated cystitis and is rated B. A pooled comparison of 11 randomized trials and 1,976 women found no significant difference in clinical resolution, with an OR of about 1.16. In Huttner 2018, however, 28-day resolution was 70% with nitrofurantoin (171/244) versus 58% with fosfomycin (139/241), a 12-percentage-point disadvantage. In SCOUT, single-dose fosfomycin was lowest among the four regimens at 59%. One-dose convenience is a product characteristic rather than superior efficacy; direct cure evidence plus repeated comparative inferiority support B with 62 points.
ads claimOne sachet cures it converts convenience into a guarantee. Fever, flank pain, pregnancy, male sex, and recurrent or complicated infection are outside this evidence.
Useful facts when choosing a product
- Prescription fosfomycin trometamol 3 g is dissolved in water and taken once for appropriately diagnosed uncomplicated cystitis in nonpregnant women.
- Oral single-dose fosfomycin should not be used for pyelonephritis with fever, chills, flank pain, or sepsis features.
- Persistent or recurrent symptoms require culture, susceptibility testing, and reassessment rather than unsupervised repeat dosing.
- Common effects include diarrhea, nausea, abdominal discomfort, headache, and vaginitis; local susceptibility matters.
What the research actually shows
Huttner 2018 randomized 513 women; 28-day clinical resolution was 70% with nitrofurantoin (171/244) versus 58% with single-dose fosfomycin (139/241), a 12-percentage-point difference (95% CI 4 to 21). Cai 2020 pooled 11 randomized trials and 1,976 women and found no significant clinical-resolution difference across comparators, OR 1.16 (95% CI 0.91 to 1.49). In the pragmatic, multicentre, open-label, randomised SCOUT trial, the primary analysis of 720 women found the lowest resolution with single-dose fosfomycin, 59% (109/185), versus 74% (128/172) with nitrofurantoin.
Why this is classified as B (62)
The pooled 11-trial, 1,976-woman analysis found no significant difference from comparators, but Huttner found 70% resolution with nitrofurantoin versus 58% with fosfomycin and SCOUT found single-dose fosfomycin lowest at 59%. Direct clinical-resolution efficacy remains established, while repeated comparative inferiority and resistance epidemiology support B with 62 points. Convenience and safety remain separate.
Counterpoint. It remains reasonable for a selected patient who cannot use nitrofurantoin or needs simple completion.
Rejudgment record. New verdict — Accepted direct clinical-cure randomized evidence while incorporating lower resolution than nitrofurantoin in 2018 and 2026 and local resistance variability
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Clinical cure of uncomplicated cystitis | B | A pooled comparison of 11 randomized trials and 1,976 women found no significant clinical-resolution difference, but cure is not guaranteed. |
| Effectiveness versus nitrofurantoin | B | Resolution was 58% versus 70% with nitrofurantoin in Huttner, a 12-point disadvantage, and the single-dose regimen was lowest at 59% in SCOUT. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Huttner A et al. 2018 | Multinational open-label randomized active control | 513 | Academic and public support | 28-day clinical resolution | Nitrofurantoin achieved 70% (171/244) versus 58% (139/241) with fosfomycin, a 12-percentage-point difference. | Key direct comparison |
| Cai T et al. 2020 | Systematic review and meta-analysis | 1,976 | Academic study | Clinical and microbiological resolution | Clinical resolution OR 1.16 (95% CI 0.91 to 1.49). | Pooled evidence |
| Llor C et al. 2026 SCOUT | Pragmatic multicenter open-label randomized trial | 720 | Public and academic support | Clinical resolution | 59% versus 74% with nitrofurantoin. | Latest direct comparison |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Single-dose fosfomycin 3 g x clinical cure of acute uncomplicated cystitis in nonpregnant women — Evidence Grade B·62. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/fosfomycin-single-dose-uncomplicated-cystitis-women/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.